U.S. Healthtech Stock News

Bristol-Myers Squibb (BMY) is being reclassified across key Russell indexes, exiting several growth benchmarks and entering the Russell 1000 Defensive and Russell 1000 Value Defensive Indexes, a shift that can influence passive fund positioning. See our latest analysis for Bristol-Myers Squibb. At a share price of US$57.62, Bristol-Myers Squibb has a year to date share price return of 7.78%, while its 1 year total shareholder return of 27.34% contrasts with a 6.66% decline over 90 days. This...

ResMed stock has fallen 23.2% over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiples currently point to the shares trading at a discount to what the business may be worth. Over the last 12 months the share price declined 23.2%, which means the market has already reset expectations even as valuation indicators lean supportive. Recent coverage has highlighted recurring revenue from sleep apnea devices and software as a potential support...

Ford Motor stock has delivered a 29.3% return over the past five years, and the latest checks suggest the market price may still sit below what both an intrinsic value estimate and market multiples imply. Over the past 5 years, Ford Motor shares have returned 29.3%, pointing to a steady, if unspectacular, payoff for long term holders. Progress on lower cost LFP batteries and energy storage can support expectations for future cash flows, while recurring recalls and product quality issues...

Autodesk (ADSK) has just been reshuffled across several Russell indices, including additions to the Russell Midcap Growth and Russell 1000 Defensive indices, while also announcing a US$350 million commitment to global AI-focused education. See our latest analysis for Autodesk. At a share price of US$194.42, Autodesk has seen its 7 day share price return rise 2.99%. However, the 30 day and year to date share price returns are down 15.95% and 32.19% respectively, while the 1 year total...

Quanta Services has delivered a very large 5 year gain of about 7x, yet the stock now screens as expensive, with a low value score and market multiples pointing to an overvalued profile despite the strong operational story around power and AI related infrastructure. Over the last 5 years, Quanta Services has returned roughly 725%, which puts extra focus on whether the current share price already reflects much of the good news. Expectations for continued demand tied to grid modernization and...

Rocket Lab stock has delivered a very large 3 year gain, yet the valuation checks now point to a richer pricing, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples indicating the shares trade at a premium rather than a clear bargain. Over the past 3 years, Rocket Lab has returned about 16x, which sets a high bar for any further upside to be justified by future cash flows. The planned acquisition of Iridium Communications and expansion into vertically...

Evolv Technologies Holdings (EVLV) drew fresh investor attention after announcing a multi-year renewal and upgrade of its hardware and software subscription agreement with TD Garden, reinforcing its role in the arena’s security screening operations. See our latest analysis for Evolv Technologies Holdings. At a share price of $5.80, Evolv Technologies Holdings has seen a 1-day share price return of 3.39% and a 7-day share price return of 4.69%. The 30-day share price return is down 10.08% and...

India’s driest June in 12 years, with rainfall nearly 40% below forecast and sharp drops in rice and oilseed sowing, is reshaping expectations for global agriculture and food trade. When a major buyer like India faces weaker crop output, attention often shifts to exporters that can step in to meet demand for staples such as rice, edible oils, pulses, and grains. This article examines how that shock filters through to large listed agriculture and food exporters and highlights 3 stocks from our...

In late June 2026, StoneX Group Inc. (NasdaqGS: SNEX) was added to the Russell 2000 Dynamic Index and expanded its capital markets offering by launching a Financial Institutions Group research practice via subsidiary The Benchmark Company, focused on regional and community banks. This combination of index inclusion and new bank-focused research deepens StoneX’s role in the regional banking ecosystem and broadens its fee-generating service capabilities. Next, we’ll examine how the new...

Fresh attention on Pilgrim's Pride (PPC) follows recent analyst coverage citing weaker earnings estimates and a lower rating, while revenue figures have shown some improvement and sentiment remains cautious. See our latest analysis for Pilgrim's Pride. At a share price of $28.11, Pilgrim's Pride has seen short term share price pressure, including a 1 day share price return that declined 2.9%, while the 3 year total shareholder return of 53.2% and 5 year total shareholder return of 51.72% show...

In June 2026, Teva Pharmaceutical Industries announced it had submitted a New Drug Application to the FDA for ecopipam, a first-in-class dopamine D1 receptor antagonist for pediatric Tourette syndrome, supported by positive Phase 3 data published in JAMA Neurology and Orphan Drug and Fast Track designations. The filing positions Teva to potentially introduce the first new FDA-approved pediatric Tourette syndrome treatment in more than a decade, extending its focus on neurology and rare...

Halozyme Therapeutics, Inc. has appointed David Ramsay as President Drug Delivery, effective June 30, 2026, giving him an enterprise-wide mandate to drive the company’s drug delivery technologies and report directly to CEO Helen Torley. This newly created role, filled by a long-tenured former Halozyme executive with deep financial and commercialization experience, points to an intensified focus on scaling the firm’s drug delivery partnerships and alliances. We’ll now examine how creating an...

NXP Semiconductors appointed Mike Lucarelli as Head of Investor Relations, succeeding retiring Senior VP Jeff Palmer. The change follows Palmer's long tenure leading the company's engagement with the investment community. Lucarelli brings extensive finance and sell side experience to the role, with a mandate to manage NXP Semiconductors' messaging to investors. NXP Semiconductors, listed as NasdaqGS:NXPI, is making this leadership change at a time when its stock has seen mixed short term...

General Mills has reported fourth-quarter 2026 sales of US$4,609.6 million and a net loss of US$2,007.9 million, driven largely by about US$1,750.0 million in goodwill and intangible asset impairments, while for the full year sales were US$18,424.6 million and the company moved from prior-year profitability to a small net loss. Despite posting a rare annual loss and booking very large impairment charges, General Mills maintained its quarterly dividend at US$0.61 per share and continued its...

Aveanna Healthcare Holdings recently delivered its fourth consecutive beat-and-raise quarter and completed the acquisition of Family First Holding, expanding its multi-state pediatric home care footprint. This combination of consistent earnings outperformance and a larger pediatric platform reinforces Aveanna’s positioning as a value-focused home care provider. Next, we’ll examine how Aveanna’s latest earnings beat and Family First acquisition may reshape the company’s broader investment...

Index removals put Brown & Brown in focus for institutional investors Brown & Brown (BRO) has been removed from several Russell growth indices, including the Russell 1000 Growth and Russell 3000 Growth benchmarks. This change is prompting index driven portfolio adjustments and fresh attention on the stock’s role in investor portfolios. See our latest analysis for Brown & Brown. At a share price of US$64.15, Brown & Brown has seen a 6.21% 7 day share price return and a 14.04% 30 day share...

Republic Services (RSG) has been in focus after reporting first quarter results that beat analyst expectations on adjusted operating income. The company also received supportive analyst ratings and regulatory approval to acquire TD*X Associates assets. See our latest analysis for Republic Services. The recent 6.3% 1 month share price return and 1.9% 7 day share price gain for Republic Services suggest firming momentum, even as the 1 year total shareholder return is down 12% and longer term 3...

Simon Property Group (SPG) is drawing attention after Wolfe Research cut its rating to Peer Perform and the stock was shifted among several Russell indexes, including additions to growth defensive groupings. See our latest analysis for Simon Property Group. The Wolfe Research downgrade came after a strong run for Simon Property Group, with a 30 day share price return of 9.15% and a year to date share price return of 21.57%. The 1 year total shareholder return of 42.62% and 3 year total...

The Supreme Court’s backing of the Federal Reserve’s independence, at a time when inflation sits above 4% and rate hikes are on the table, puts interest rate policy firmly in the spotlight for bank investors. Higher rates can reshape funding costs, loan demand, and profit margins, which matters directly for larger US, UK, and Canadian banks with solid balance sheets. This article explains how that backdrop connects to our Banking Sector Stocks screener and highlights 3 stocks that appear well...

Why NIO Stock Is Back in Focus After June Delivery Update NIO (NIO) reported 40,597 vehicle deliveries in June 2026 and 107,658 for the second quarter, with the stock reacting as investors weighed record monthly volume against a quarterly total that missed earlier guidance. See our latest analysis for NIO. The latest delivery update landed against a mixed price backdrop for NIO, with the 1-day share price return of 2.22% standing out against a 30-day share price return down 9.64% and a 5-year...

Index removal puts Mineralys Therapeutics in focus Mineralys Therapeutics (MLYS) was recently removed from several Russell indexes, including the Russell 3000E and Russell Microcap series. This type of change can shift trading flows and short term demand for the stock. See our latest analysis for Mineralys Therapeutics. At a share price of $26.98, Mineralys Therapeutics has seen short term share price pressure, with the 30 day share price return down 14.35%, even as the 1 year total...

Recent Performance Snapshot for John B. Sanfilippo & Son Stock John B. Sanfilippo & Son (JBSS) has drawn attention after a recent daily decline of 2.8%, even as the stock shows gains of 5.3% over the past week and about 15% over the past month. Investors are weighing that short term pullback against year to date and 1 year total returns of 23.2% and 37.3% respectively, alongside a reported market value of about US$1.0b and annual revenue of US$1,164.3m. See our latest analysis for John B...

J&J Snack Foods (JJSF) is being shifted across several Russell indexes, moving out of multiple growth benchmarks and into value focused and value defensive indexes, a change that can influence index fund trading. See our latest analysis for J&J Snack Foods. For context, J&J Snack Foods’ share price is at US$73.45, with the stock down 18.86% on a year to date share price basis and the 5 year total shareholder return declining 52.36%. This points to fading momentum even before this shift into...

On 27 June 2026, Lexicon Pharmaceuticals, Inc. was added to a wide range of Russell indexes, including the Russell 2000, Russell 2500, Russell 3000 and related growth, microcap and completeness benchmarks, significantly expanding its presence across these index families. This broad index inclusion increases Lexicon’s visibility with institutional investors and index-tracking funds, potentially affecting trading volumes, ownership mix, and how the market assesses its pipeline-driven...